TRPX Stock Price – Therapix Biosciences Ltd. ADR Stock Quote (U.S.: Nasdaq)

0
224


Therapix shares surge 30% premarket on news of positive trial of Tourette syndrome treatment

Therapix Biosciences Ltd. shares soared more than 30% in premarket trade Monday, after the company reported positive results in a trial of a treatment for Tourette syndrome. The company said a phase IIa study of its proprietary cannabinoid product platform THX-IIO significantly improved symptoms of the condition over time. “These results are of particular interest as the pharmacology of THX-110 appears to be distinct from existing medications for TS and may offer a unique option for treating these patients,” Chief Technology Officer Adi Zuloff-Shani said in a statement. Sixteen patients participated in the study and the company is now planning a further placebo-controlled trial. Tourette syndrome is a neurological condition that is characterized by involuntary tics and vocalizations, that can include streams of swearing and obscene language. Therapix shares have fallen 30% in the last 12 months, while the S&P 500 has gained 11%.




Source : MTV